Case Study: Project and Portfolio Value Creation makes confident multimillion-dollar investment decisions with Palisade's PrecisionTree

How PrecisionTree Helped a Biopharmaceutical Company Decide between Multimillion Dollar Investments

Project and Portfolio Value Creation, led by Richard Bayney, helped a major biopharmaceutical company facing a choice between two multimillion-dollar investments—$325M in compound ABC for Alzheimer’s Disease versus $550M in compound XYZ for MCI and GAD—under high clinical, regulatory and commercial uncertainty. To bring clarity to this phase‑based decision problem, the team used Palisade’s PrecisionTree to structure the analysis and capture SME judgments.

Using Palisade’s PrecisionTree, Bayney and colleagues built multi‑phase decision trees with probabilities and commercial scenarios, computed risk‑adjusted NPVs (eNPVs), and ran sensitivity analyses to find breakpoints and test robustness. The work showed an eNPV advantage for XYZ ($290M vs $245M for ABC), and the sensitivity testing strengthened SME confidence and enabled a defensible, data‑driven investment recommendation.

Project and Portfolio Value Creation

Richard Bayney

Project and Portfolio Value Creation